{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T20:52:18Z","timestamp":1771879938730,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd001417.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T00:00:00Z","timestamp":1571788800000}}],"reference-count":73,"publisher":"Wiley","issue":"10","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd001417.pub4","type":"journal-article","created":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T18:44:48Z","timestamp":1571856288000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Topiramate add-on therapy for drug-resistant focal epilepsy"],"prefix":"10.1002","volume":"2019","author":[{"given":"Rebecca","family":"Bresnahan","sequence":"first","affiliation":[{"name":"Institute of Translational Medicine, University of Liverpool; Department of Molecular and Clinical Pharmacology; Lower Lane Liverpool UK L9 7LJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliet","family":"Hounsome","sequence":"additional","affiliation":[{"name":"University of Liverpool; Liverpool Reviews and Implementation Group; Sherrington Building Ashton Street Liverpool UK L69 3GE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Jette","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai; Neurology; One Gustave L. Levey Place Box 1137 New York New York USA 10029"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane L","family":"Hutton","sequence":"additional","affiliation":[{"name":"University of Warwick; Department of Statistics; Coventry UK CV4 7AL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony G","family":"Marson","sequence":"additional","affiliation":[{"name":"Institute of Translational Medicine, University of Liverpool; Department of Molecular and Clinical Pharmacology; Lower Lane Liverpool UK L9 7LJ"},{"name":"The Walton Centre NHS Foundation Trust; Liverpool UK"},{"name":"Liverpool Health Partners; Liverpool UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,10,23]]},"reference":[{"issue":"Suppl 3","key":"10.1002\/14651858.CD001417.pub4-BIB0001|cit1","first-page":"S150","article-title":"Double-blind, placebo-controlled trial of 800 mg\/day topiramate as add-on therapy in patients with refractory partial epilepsy","volume":"36","author":"Ben-Menachem","year":"1995","journal-title":"Epilepsia"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD001417.pub4-BIB0002|cit2","first-page":"109","article-title":"Topiramate add-on treatment in patients with intractable partial epilepsy: a multicenter study","volume":"34","author":"Ben-Menachem","year":"1993","journal-title":"Epilepsia"},{"issue":"6","key":"10.1002\/14651858.CD001417.pub4-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1528-1157.1996.tb00606.x","article-title":"Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures","volume":"37","author":"Ben-Menachem","year":"1996","journal-title":"Epilepsia"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD001417.pub4-BIB0004|cit4","first-page":"S149","article-title":"Double-blind, placebo-controlled trial of 400 mg\/day topiramate as add-on therapy in patients with refractory partial epilepsy","volume":"36","author":"Martinez-Lage","year":"1995","journal-title":"Epilepsia"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD001417.pub4-BIB0005|cit5","first-page":"105","article-title":"Topiramate as add-on therapy in refractory partial epilepsy","volume":"33","author":"Ostergard","year":"1992","journal-title":"Epilepsia"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD001417.pub4-BIB0006|cit6","first-page":"105, Abstract n","article-title":"USL255, a once-daily, extended-release topiramate, has positive effects on clinical outcomes and quality of life: results from the phase 3 PREVAIL clinical trial","volume":"14","author":"Arnold","year":"2014","journal-title":"Epilepsy Currents"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD001417.pub4-BIB0007|cit7","first-page":"42-43, Abstract","article-title":"Efficacy and safety of USL255, once-daily extended-release topiramate, in adults with partial onset seizures: the PREVAIL study","volume":"55","author":"Blatt","year":"2014","journal-title":"Epilepsia"},{"issue":"10 Suppl","key":"10.1002\/14651858.CD001417.pub4-BIB0008|cit8","first-page":"Abstract no: P3","article-title":"Efficacy of USL255 across partial-onset seizure types and refractory patient status: subgroup analyses from the PREVAIL study","volume":"82","author":"Blatt","year":"2014","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD001417.pub4-BIB0009|cit9","first-page":"204, Abstract n","article-title":"USL255 is efficacious across all partial-onset seizure types and with a variety of concomitant antiepileptic drugs: Results from subgroup analyses of the phase 3 PREVAIL clinical trial","volume":"14","author":"Blatt","year":"2014","journal-title":"Epilepsy Currents"},{"issue":"10","key":"10.1002\/14651858.CD001417.pub4-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1586\/14737175.2014.958470","article-title":"USL255 extended-release topiramate for the treatment of epilepsy","volume":"14","author":"Chung","year":"2014","journal-title":"Expert Review of Neurotherapeutics"},{"issue":"3","key":"10.1002\/14651858.CD001417.pub4-BIB0013|cit11","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/1756285615578406","article-title":"A review of the efficacy and safety of extended-release topiramate in the adjunctive treatment for refractory partial-onset seizures","volume":"8","author":"Chung","year":"2015","journal-title":"Therapeutic Advances in Neurological Disorders"},{"issue":"7","key":"10.1002\/14651858.CD001417.pub4-BIB0011|cit12","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1111\/epi.12660","article-title":"Once-daily USL255 as adjunctive treatment of partial-onset seizures: randomized phase III study","volume":"55","author":"Chung","year":"2014","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001417.pub4-BIB0012|cit13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.yebeh.2016.03.005","article-title":"Long-term safety and sustained efficacy of USL255 (topiramate extended-release capsules) in patients with refractory partial-onset seizures","volume":"59","author":"Chung","year":"2016","journal-title":"Epilepsy & Behavior"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD001417.pub4-BIB0014|cit14","first-page":"142-3, Abstract","article-title":"Efficacy of USL255 (qudexyTM XR; Extended-release topiramate) in patients with refractory partial-onset seizures: PREVAIL and PREVAIL OLE","volume":"15","author":"Clark","year":"2015","journal-title":"Epilepsy Currents"},{"issue":"10 Suppl","key":"10.1002\/14651858.CD001417.pub4-BIB0015|cit15","first-page":"Abstract no: P3","article-title":"Adverse event profile of USL255 in patients with refractory partial-onset seizures: the PREVAIL study","volume":"82","author":"Hogan","year":"2014","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD001417.pub4-BIB0016|cit16","first-page":"103-4, Abstract","article-title":"Safety and tolerability of USL255 in subjects with refractory partial-onset seizures: results from the randomized, phase 3 PREVAIL clinical trial","volume":"14","author":"Hogan","year":"2014","journal-title":"Epilepsy Currents"},{"key":"10.1002\/14651858.CD001417.pub4-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.yebeh.2014.09.061","article-title":"Efficacy of once-daily extended-release topiramate (USL255): a subgroup analysis based on the level of treatment resistance","volume":"41","author":"Hogan","year":"2014","journal-title":"Epilepsy & Behavior"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD001417.pub4-BIB0018|cit18","first-page":"104, Abstract n","article-title":"Time to onset of efficacy and sustained treatment effects of USL255: results from the phase 3 PREVAIL clinical trial","volume":"14","author":"Lawson","year":"2014","journal-title":"Epilepsy Currents"},{"issue":"10 Suppl","key":"10.1002\/14651858.CD001417.pub4-BIB0019|cit19","first-page":"Abstract no: P3","article-title":"Early onset of efficacy and safety outcomes with USL255 treatment: The PREVAIL study","volume":"82","author":"Nagaraddi","year":"2014","journal-title":"Neurology"},{"issue":"7","key":"10.1002\/14651858.CD001417.pub4-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1212\/WNL.52.7.1338","article-title":"A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children","volume":"52","author":"Elterman","year":"1999","journal-title":"Neurology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD001417.pub4-BIB0022|cit21","first-page":"33, Abstract no","article-title":"Topiramate dose-ranging trial in refractory partial epilepsy","volume":"36","author":"Faught","year":"1995","journal-title":"Epilepsia"},{"issue":"6","key":"10.1002\/14651858.CD001417.pub4-BIB0021|cit22","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1212\/WNL.46.6.1684","article-title":"Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages","volume":"46","author":"Faught","year":"1996","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD001417.pub4-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1034\/j.1600-0404.2002.02071.x","article-title":"Low-dose topiramate in adults with treatment-resistant partial-onset seizures","volume":"106","author":"Guberman","year":"2002","journal-title":"Acta Neurologica Scandinavica"},{"issue":"Suppl 7","key":"10.1002\/14651858.CD001417.pub4-BIB0024|cit24","first-page":"179-80, Abstrac","article-title":"Efficacy of 200 mg\/day topiramate in treatment-resistant partial seizures when added to an enzyme-inducing anti-epileptic drug (AED)","volume":"42","author":"Guberman","year":"2001","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001417.pub4-BIB0025|cit25","first-page":"35","article-title":"Efficacy and tolerability of 200 mg\/day topiramate in a placebo-controlled comparison of titration rates","volume":"41","author":"Neto","year":"2000","journal-title":"Epilepsia"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD001417.pub4-BIB0026|cit26","first-page":"152, Abstract n","article-title":"Weight reduction during topiramate treatment of partial seizures","volume":"43","author":"Oene","year":"2002","journal-title":"Epilepsia"},{"issue":"12","key":"10.1002\/14651858.CD001417.pub4-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1111\/j.1528-1157.1999.tb01596.x","article-title":"Topiramate in medically intractable partial epilepsies: double-blind placebo-controlled randomized parallel group trial","volume":"40","author":"Korean Topiramate Study Group","year":"1999","journal-title":"Epilepsia"},{"issue":"6","key":"10.1002\/14651858.CD001417.pub4-BIB0028|cit28","first-page":"809","article-title":"Double-blind placebo-controlled randomized clinical trial of topiramate add-on therapy in medically intractable partial epilepsies","volume":"16","author":"Lee","year":"1998","journal-title":"Journal of the Korean Neurology Association"},{"issue":"6","key":"10.1002\/14651858.CD001417.pub4-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1212\/WNL.46.6.1678","article-title":"Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages","volume":"46","author":"Privitera","year":"1996","journal-title":"Neurology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD001417.pub4-BIB0030|cit30","first-page":"33, Abstract no","article-title":"Dose-ranging trial with higher doses of topiramate in patients with resistant partial seizures","volume":"36","author":"Privitera","year":"1995","journal-title":"Epilepsia"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD001417.pub4-BIB0031|cit31","first-page":"153, Abstract n","article-title":"Placebo-controlled trial of topiramate as adjunctive therapy to carbamazepine or phenytoin for partial-onset seizures","volume":"37","author":"Rosenfeld","year":"1996","journal-title":"Epilepsia"},{"issue":"3","key":"10.1002\/14651858.CD001417.pub4-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0920-1211(96)00029-0","article-title":"Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy","volume":"25","author":"Sharief","year":"1996","journal-title":"Epilepsy Research"},{"key":"10.1002\/14651858.CD001417.pub4-BIB0033|cit33","first-page":"41","article-title":"Adjuvant topiramate treatment in intractable partial epilepsy","volume":"6","author":"Sharief","year":"1993","journal-title":"Epilepsia"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD001417.pub4-BIB0034|cit34","first-page":"S150","article-title":"Double-blind, placebo-controlled trial of 600 mg\/day topiramate as add-on therapy in patients with refractory partial epilepsy","volume":"36","author":"Tassinari","year":"1995","journal-title":"Epilepsia"},{"issue":"8","key":"10.1002\/14651858.CD001417.pub4-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1528-1157.1996.tb00649.x","article-title":"Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy","volume":"37","author":"Tassinari","year":"1996","journal-title":"Epilepsia"},{"issue":"9","key":"10.1002\/14651858.CD001417.pub4-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/j.1528-1157.2000.tb00321.x","article-title":"A double-blind, placebo-controlled study of topiramate in adult patients with refractory partial epilepsy","volume":"41","author":"Yen","year":"2000","journal-title":"Epilepsia"},{"issue":"2","key":"10.1002\/14651858.CD001417.pub4-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1177\/147323001103900208","article-title":"Topiramate as an adjunctive treatment for refractory partial epilepsy in the elderly","volume":"39","author":"Zhang","year":"2011","journal-title":"Journal of International Medical Research"},{"issue":"9","key":"10.1002\/14651858.CD001417.pub4-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1212\/01.WNL.0000091867.09720.6B","article-title":"Randomized, concentration-controlled trail of topiramate in refractory focal epilepsy","volume":"61","author":"Christensen","year":"2003","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD001417.pub4-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.4081\/ni.2009.e6","article-title":"Cognitive effects of lamotrigine versus topiramate as adjunctive therapy in older adults with epilepsy","volume":"1","author":"Chung","year":"2009","journal-title":"Neurology international"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD001417.pub4-BIB0040|cit40","first-page":"285","article-title":"Seizure severity in patients with partial onset (POS) or primary generalised tonic-clonic (PGTC) seizures following treatment with topiramate. A comparison of two different methodologies in a randomised controlled trial","volume":"40","author":"Coles","year":"1999","journal-title":"Epilepsia"},{"issue":"9","key":"10.1002\/14651858.CD001417.pub4-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1212\/WNL.0b013e3181d1cd4c","article-title":"Randomized trial of adjunctive topiramate therapy in infants with refractory partial seizures","volume":"74","author":"Novotny","year":"2010","journal-title":"Neurology"},{"issue":"Suppl 7","key":"10.1002\/14651858.CD001417.pub4-BIB0042|cit42","first-page":"233, Abstract n","article-title":"A randomized, double-blind, placebo-controlled study of topiramate as an adjunct to anticonvulsant therapy in infants with refractory partial onset seizures","volume":"49","author":"Renfroe","year":"2008","journal-title":"Epilepsia"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD001417.pub4-BIB0043|cit43","first-page":"114, Abstract n","article-title":"Topiramate (TPM) in older adults with partial-onset seizures: a double-blind, dose-comparison study","volume":"46","author":"Ramsay","year":"2005","journal-title":"Epilepsia"},{"issue":"7","key":"10.1002\/14651858.CD001417.pub4-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/j.1528-1167.2008.01584.x","article-title":"Topiramate in older patients with partial-onset seizures: a pilot double-blind, dose-comparison study","volume":"49","author":"Ramsay","year":"2008","journal-title":"Epilepsia"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD001417.pub4-BIB0045|cit45","first-page":"11","article-title":"Safety and effectiveness of three oral doses of topiramate in the treatment of patients with refractory partial epilepsy","volume":"32","author":"Aranguiz","year":"1991","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001417.pub4-BIB0046|cit46","first-page":"38","article-title":"Efficacy of therapy with new antiepileptic drugs (tiagabine, gabapentin, topiramate) in drug-resistant epilepsy","volume":"41","author":"Kazibutowska","year":"2000","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001417.pub4-BIB0047|cit47","unstructured":"Brown SD Wolf HH Swinyard EA Twyman RE White HS The novel anticonvulsant topiramate enhances GABA-mediated chloride flux Epilepsia 1993 122 3"},{"issue":"8968","key":"10.1002\/14651858.CD001417.pub4-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0140-6736(95)91208-8","article-title":"Remission of epilepsy: results from the national general practice study of epilepsy","volume":"346","author":"Cockerell","year":"1995","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD001417.pub4-BIB0049|cit49","first-page":"123","article-title":"Selective effects of topiramate on sustained repetitive firing and spontaneous bursting in cultured hippocampal neurons","volume":"34","author":"Coulter","year":"1993","journal-title":"Epilepsia"},{"issue":"3","key":"10.1002\/14651858.CD001417.pub4-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1212\/WNL.0000000000003509","article-title":"Prevalence and incidence of epilepsy: A systematic review and meta-analysis of international studies","volume":"88","author":"Fiest","year":"2017","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001417.pub4-BIB0051|cit51","unstructured":"McMaster University (developed by Evidence Prime) GRADEpro GDT 2015"},{"issue":"18","key":"10.1002\/14651858.CD001417.pub4-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"7069","DOI":"10.1523\/JNEUROSCI.23-18-07069.2003","article-title":"Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons","volume":"23","author":"Gryder","year":"2003","journal-title":"The Journal of Neuroscience"},{"issue":"2","key":"10.1002\/14651858.CD001417.pub4-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0028-3908(01)00171-X","article-title":"Two new actions of topiramate: inhibition of depolarizing GABA(A)-mediated responses and activation of a potassium conductance","volume":"42","author":"Herrero","year":"2002","journal-title":"Neuropharmacology"},{"key":"10.1002\/14651858.CD001417.pub4-BIB0054|cit54","unstructured":"Higgins JP Green S editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD001417.pub4-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"c365","DOI":"10.1136\/bmj.c365","article-title":"The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews","volume":"340","author":"Kirkham","year":"2010","journal-title":"BMJ"},{"issue":"5","key":"10.1002\/14651858.CD001417.pub4-BIB0056|cit56","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD001417.pub4-BIB0057|cit57","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"3","key":"10.1002\/14651858.CD001417.pub4-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1136\/bmjebm-2018-110891","article-title":"The effect of publication bias magnitude and direction on the certainty in evidence","volume":"23","author":"Murad","year":"2018","journal-title":"BMJ Evidence-Based Medicine"},{"issue":"4","key":"10.1002\/14651858.CD001417.pub4-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1006\/phrs.1997.0124","article-title":"A pharmacological and clinical review on topiramate, a new antiepileptic drug","volume":"35","author":"Perucca","year":"1997","journal-title":"Pharmacological Research"},{"issue":"10","key":"10.1002\/14651858.CD001417.pub4-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1177\/106002809703101010","article-title":"Topiramate: a new antiepileptic drug","volume":"31","author":"Privitera","year":"1997","journal-title":"The Annals of Pharmacotherapy"},{"key":"10.1002\/14651858.CD001417.pub4-BIB0061|cit61","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014"},{"issue":"4","key":"10.1002\/14651858.CD001417.pub4-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1528-1157.1981.tb06158.x","article-title":"Phenytoin for epilepsy: a long term prospective study, assisted by serum level monitoring, in previously untreated patients","volume":"22","author":"Reynolds","year":"1981","journal-title":"Epilepsia"},{"issue":"4","key":"10.1002\/14651858.CD001417.pub4-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001417.pub4-BIB0064|cit64","unstructured":"Sch\u00fcnemann H Bro\u017cek J Guyatt G Oxman A editor(s) Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013 Available from gdt.guidelinedevelopment.org\/app\/handbook\/handbook.html"},{"issue":"24","key":"10.1002\/14651858.CD001417.pub4-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1002\/1097-0258(20001230)19:24<3417::AID-SIM614>3.0.CO;2-L","article-title":"A multilevel model framework for meta-analysis of clinical trials with binary outcomes","volume":"19","author":"Turner","year":"2000","journal-title":"Statistics in Medicine"},{"issue":"1","key":"10.1002\/14651858.CD001417.pub4-BIB0066|cit66","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001417","article-title":"TOPIRAMATE FOR DRUG RESISTANT PARTIAL EPILEPSY","author":"Jette","year":"1999","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD001417.pub4-BIB0067|cit67","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001417","article-title":"TOPIRAMATE IN DRUG-RESISTANT PARTIAL EPILEPSY","author":"Jette","year":"1999","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD001417.pub4-BIB0068|cit68","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001417","article-title":"Topiramate for drug-resistant partial epilepsy","author":"Jette","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD001417.pub4-BIB0069|cit69","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001417","article-title":"Topiramate add-on for drug-resistant partial epilepsy","author":"Jette","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD001417.pub4-BIB0070|cit70","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001417.pub2","article-title":"Topiramate add-on for drug-resistant partial epilepsy","author":"Jette","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD001417.pub4-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1136\/bmj.313.7066.1169","article-title":"New antiepileptic drugs; a systematic review of their efficacy and tolerability","volume":"313","author":"Marson","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD001417.pub4-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1528-1157.1997.tb01251.x","article-title":"The new antiepileptic drugs; a systematic review of their efficacy and tolerability","volume":"38","author":"Marson","year":"1997","journal-title":"Epilepsia"},{"issue":"2","key":"10.1002\/14651858.CD001417.pub4-BIB0073|cit73","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001417.pub3","article-title":"Topiramate add-on for drug-resistant partial epilepsy","author":"Pulman","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD001417.pub4\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,7]],"date-time":"2021-11-07T17:17:09Z","timestamp":1636305429000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD001417.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Epilepsy Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,10,23]]},"references-count":73,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,10]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd001417.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,23]]}}}